Mt. Sinai Comprehensive Cancer Center
Welcome,         Profile    Billing    Logout  
 19 Trials 
33 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Schwartz, Michael A
A011801, NCT04457596: T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

Calendar Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer
Recruiting
3
1031
Canada, US
Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.
Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Synchronous Bilateral Breast Carcinoma
01/28
05/35
STIMVAX, NCT04444622: Immunotherapy for Third Line Metastatic Colorectal Cancer

Recruiting
2
24
US
AlloStim, StimVax
Immunovative Therapies, Ltd., Mirror Biologics, Inc.
Metastatic Colorectal Cancer
11/24
04/25
SABER, NCT06366087: Sublingual Atropine Bioequivalence by Route of Administration

Not yet recruiting
1
46
US
Atropine Sulfate Ophthalmic Solution USP, 1%, Atropine Sulfate Injection, USP 8 mg/20 mL (0.4 mg/mL)
Biomedical Advanced Research and Development Authority, Rho Federal Systems Division, Inc., Allucent
Atropine Bioequivalence
05/24
05/24
#HOPE4KIDNEY, NCT05820087: The HistoSonics Edison™ System for Treatment of Primary Solid Renal Tumors Using Histotripsy

Recruiting
N/A
68
US
HistoSonics Edison System, Histotripsy
HistoSonics, Inc.
Renal Cancer, Tumor, Solid, Kidney Cancer, Tumor, Tumor, Benign
12/24
12/29
Barrientos, Jacqueline
STIMVAX, NCT04444622: Immunotherapy for Third Line Metastatic Colorectal Cancer

Recruiting
2
24
US
AlloStim, StimVax
Immunovative Therapies, Ltd., Mirror Biologics, Inc.
Metastatic Colorectal Cancer
11/24
04/25
CIRLL study, NCT03420183: A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies

Recruiting
1b
156
US
Cirmtuzumab followed by Cirmtuzumab plus ibrutinib, UC-961, Imbruvica, Cirmtuzumab plus ibrutinib, Ibrutinib
Oncternal Therapeutics, Inc, University of California, San Diego, California Institute for Regenerative Medicine (CIRM)
B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma
04/19
12/22
C1763102, NCT05602363: AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

Recruiting
1
110
US
AS-1763
Carna Biosciences, Inc.
B-cell Malignancy, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma
09/27
09/27
Enriquez-Nunez, Yvonne
NCT04507503: Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

Approved for marketing
N/A
US
TAS-120, Futibatinib
Taiho Oncology, Inc.
Advanced Cholangiocarcinoma
 
 
Cusnir, Mike
VERACITY, NCT04844749: Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent

Terminated
3
105
US
VERU-111, Sabizabulin, Enzalutamide, Abiraterone, XTANDI, Zytiga
Veru Inc.
Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer
05/23
05/23
PANOVA-3, NCT03377491: Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel

Active, not recruiting
3
556
Europe, Canada, US, RoW
NovoTTF-200T, TTFields, Gemcitabine, nab paclitaxel
NovoCure Ltd.
Pancreas Adenocarcinoma
09/24
10/24
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen Inc., Merck Sharp & Dohme LLC
Colorectal Neoplasms
08/25
04/28
FIRST-308, NCT05948475: Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

Recruiting
3
200
Europe, US, RoW
Tinengotinib 8 mg, Tinengotinib 10 mg, Physician's Choice
TransThera Sciences (Nanjing), Inc.
Cholangiocarcinoma
05/26
08/26
DORA, NCT03574571: A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

Recruiting
3
738
Europe, US, RoW
Docetaxel 75 mg/m2, Docetaxel 60 mg/m2, Radium-223
Memorial Sloan Kettering Cancer Center, Bayer
Prostate Cancer
06/26
06/26
GRANITE, NCT05141721: A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer

Active, not recruiting
2/3
700
US
GRT-C901, GRT-R902, Atezolizumab, Tecentriq, Ipilimumab, Yervoy, Fluoropyrimidine plus leucovorin, Xeloda, Bevacizumab, Avastin
Gritstone bio, Inc.
Colorectal Neoplasms
03/27
03/27
STIMVAX, NCT04444622: Immunotherapy for Third Line Metastatic Colorectal Cancer

Recruiting
2
24
US
AlloStim, StimVax
Immunovative Therapies, Ltd., Mirror Biologics, Inc.
Metastatic Colorectal Cancer
11/24
04/25
NCT04919642: Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma

Completed
2
55
US
TT-00420
TransThera Sciences (Nanjing), Inc.
Cholangiocarcinoma, FGFR2 Fusion, FGFR2 Gene Mutation, FGFR1 Alteration, FGFR3 Alteration
02/24
02/24
NCT04169347: FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer

Active, not recruiting
2
27
US
Oxaliplatin, Irinotecan, Leucovorin, Panitumumab
Criterium, Inc., Amgen
Colorectal Cancer Metastatic
12/24
01/25
NCT05945823: Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

Recruiting
2
66
Europe, US
Futibatinib, TAS-120, Pembrolizumab, MK-3475, KEYTRUDA®, Cisplatin, PLATINOL®, 5-FU, ADRUCIL®, Oxaliplatin, ELOXATIN®, Leucovorin, calcium folinate, folinic acid, WELLCOVORIN®, Levoleucovorin, calcium levofolinate, levofolinic acid, FUSILEV®, Irinotecan
Taiho Oncology, Inc.
Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer, Siewert Type 1 GEJ Cancer, Pancreatic Cancer
01/25
05/25
1-BETTER, NCT04825288: XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer

Active, not recruiting
1/2
69
US
XB2001 or Placebo
XBiotech, Inc.
Pancreatic Cancer
02/24
05/24
KEYNOTE-E58, NCT04041310: Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors

Recruiting
1/2
115
Europe, Canada, US
GAd-209-FSP low dose, MVA-209-FSP low dose, GAd-209-FSP high dose, MVA-209-FSP high dose, GAd20-209-FSP, RP2D, MVA-209-FSP, RP2D, KEYTRUDA®, pembrolizumab
Nouscom SRL, Merck Sharp & Dohme LLC
Solid Tumor, Adult
03/25
07/26
NCT04507503: Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

Approved for marketing
N/A
US
TAS-120, Futibatinib
Taiho Oncology, Inc.
Advanced Cholangiocarcinoma
 
 
MRD, NCT05210283: CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer

Recruiting
N/A
750
Canada, US
MRD
Exact Sciences Corporation, NSABP Foundation Inc
Colorectal Cancer
02/28
02/28
Gligich, Oleg
ASTRIDE, NCT05468489: To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

Recruiting
3
200
US
Serplulimab + chemotherapy (carboplatin-etoposide), Atezolizumab + chemotherapy (carboplatin-etoposide)
Shanghai Henlius Biotech
Extensive Stage Small Cell Lung Cancer
10/24
12/25
SWOG S2302, NCT05633602: Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

Recruiting
3
700
US
Chemotherapy, Chemo, Chemotherapy (NOS), Chemotherapy, Cancer, General, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Ramucirumab, Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, IMC-1121B, LY3009806
SWOG Cancer Research Network, National Cancer Institute (NCI), Eli Lilly and Company, Merck Sharp & Dohme LLC
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
03/25
03/28
STIMVAX, NCT04444622: Immunotherapy for Third Line Metastatic Colorectal Cancer

Recruiting
2
24
US
AlloStim, StimVax
Immunovative Therapies, Ltd., Mirror Biologics, Inc.
Metastatic Colorectal Cancer
11/24
04/25
NCT05469178 / 2019-003806-28: A Study to Investigate the Safety, Tolerability, and Preliminary Anti-tumor Activity of Bemcentinib in Combination With Pembrolizumab Plus Pemetrexed and Carboplatin in Adult Participants With Untreated Non-squamous Non-small Cell Lung Cancer

Recruiting
1b/2a
64
US
Bemcentinib, Pembrolizumab, Pemetrexed, Carboplatin
BerGenBio ASA, BerGenBio ASA
Carcinoma, Non-Small-Cell Lung
08/25
08/25
Chaaya, Gerard
STIMVAX, NCT04444622: Immunotherapy for Third Line Metastatic Colorectal Cancer

Recruiting
2
24
US
AlloStim, StimVax
Immunovative Therapies, Ltd., Mirror Biologics, Inc.
Metastatic Colorectal Cancer
11/24
04/25
Gopalakrishnan, Ragisha
STIMVAX, NCT04444622: Immunotherapy for Third Line Metastatic Colorectal Cancer

Recruiting
2
24
US
AlloStim, StimVax
Immunovative Therapies, Ltd., Mirror Biologics, Inc.
Metastatic Colorectal Cancer
11/24
04/25
NCT05230810: Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.

Recruiting
1/2
40
US
Alpelisib, Piqray, Tucatinib, Tukysa, Fulvestrant, Faslodex,
Criterium, Inc., Novartis, Seagen Inc.
HER2-positive Metastatic Breast Cancer
08/24
06/25
HyperlynX, NCT06056310: Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN

Recruiting
1
40
Europe, US, RoW
Xevinapant, Debio 1143, Cisplatin, intensity-modulated radiation therapy (IMRT)
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Head and Neck Cancer
04/25
04/25
Caso, Irina Bakura
1-BETTER, NCT04825288: XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer

Active, not recruiting
1/2
69
US
XB2001 or Placebo
XBiotech, Inc.
Pancreatic Cancer
02/24
05/24
Simkins, Aron
STIMVAX, NCT04444622: Immunotherapy for Third Line Metastatic Colorectal Cancer

Recruiting
2
24
US
AlloStim, StimVax
Immunovative Therapies, Ltd., Mirror Biologics, Inc.
Metastatic Colorectal Cancer
11/24
04/25
Smith, Luz
STIMVAX, NCT04444622: Immunotherapy for Third Line Metastatic Colorectal Cancer

Recruiting
2
24
US
AlloStim, StimVax
Immunovative Therapies, Ltd., Mirror Biologics, Inc.
Metastatic Colorectal Cancer
11/24
04/25

Download Options